LY 300168

Drug Profile

LY 300168

Alternative Names: GYKI 53655

Latest Information Update: 14 Sep 2000

Price : $50

At a glance

  • Originator Egis Pharmaceuticals; Eli Lilly
  • Developer Eli Lilly
  • Class Antiepileptic drugs; Benzodiazepines; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Opioid abuse

Most Recent Events

  • 14 Sep 2000 Discontinued-Preclinical for Neuroprotection in USA (Unknown route)
  • 14 Sep 2000 Discontinued-Preclinical for Opioid abuse in USA (Unknown route)
  • 18 Feb 1999 Preclinical development for Neuroprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top